Literature DB >> 22246683

Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response.

James S Testa1, Vivekananda Shetty, Gomathinayagam Sinnathamby, Zacharie Nickens, Julie Hafner, Shivali Kamal, Xianchao Zhang, Marti Jett, Ramila Philip.   

Abstract

Dengue fever and dengue hemorrhagic fever are significant global public health problems, and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T-cell responses. Currently, there are no available tools to assess protective T-cell responses during infection or after vaccination. In this study, we utilize an immunoproteomics process to uncover novel HLA-A2-specific epitopes derived from dengue virus (DV)-infected cells. These epitopes are conserved, and we report that epitope-specific cytotoxic lymphocytes (CTLs) are cross-reactive against all 4 DV serotypes. These epitopes have potential as new informational and diagnostic tools to characterize T-cell immunity in DV infection and may serve as part of a universal vaccine candidate complementary to current vaccines in trial.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22246683      PMCID: PMC3297201          DOI: 10.1093/infdis/jir814

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  43 in total

1.  Serotype-specific T(H)1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines.

Authors:  William Gwinn; Wellington Sun; Bruce L Innis; Jeffrey Caudill; Alan D King
Journal:  Am J Trop Med Hyg       Date:  2003-12       Impact factor: 2.345

Review 2.  Synthetic peptides as vaccines.

Authors:  R Arnon; R J Horwitz
Journal:  Curr Opin Immunol       Date:  1992-08       Impact factor: 7.486

3.  Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes.

Authors:  Barbara W Johnson; Trudy V Chambers; Mary B Crabtree; Tejal R Bhatt; Farshad Guirakhoo; Thomas P Monath; Barry R Miller
Journal:  Am J Trop Med Hyg       Date:  2002-09       Impact factor: 2.345

4.  Synthetic peptides: a next generation of vaccines?

Authors:  M W Steward; C R Howard
Journal:  Immunol Today       Date:  1987

5.  Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques.

Authors:  K Raviprakash; K R Porter; T J Kochel; D Ewing; M Simmons; I Phillips; G S Murphy; W R Weiss; C G Hayes
Journal:  J Gen Virol       Date:  2000-07       Impact factor: 3.891

6.  Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones.

Authors:  S J Gagnon; W Zeng; I Kurane; F A Ennis
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  T-helper cell epitopes on the E-glycoprotein of dengue 2 Jamaica virus.

Authors:  J T Roehrig; P A Risi; J R Brubaker; A R Hunt; B J Beaty; D W Trent; J H Mathews
Journal:  Virology       Date:  1994-01       Impact factor: 3.616

8.  Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.

Authors:  Timothy P Endy; Ananda Nisalak; Supamit Chunsuttitwat; David W Vaughn; Sharone Green; Francis A Ennis; Alan L Rothman; Daniel H Libraty
Journal:  J Infect Dis       Date:  2004-03-01       Impact factor: 5.226

9.  Dengue virus protein recognition by virus-specific murine CD8+ cytotoxic T lymphocytes.

Authors:  A L Rothman; I Kurane; C J Lai; M Bray; B Falgout; R Men; F A Ennis
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

10.  Immunodominant T-cell responses to dengue virus NS3 are associated with DHF.

Authors:  Thaneeya Duangchinda; Wanwisa Dejnirattisai; Sirijit Vasanawathana; Wannee Limpitikul; Nattaya Tangthawornchaikul; Prida Malasit; Juthathip Mongkolsapaya; Gavin Screaton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-13       Impact factor: 11.205

View more
  11 in total

1.  Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals.

Authors:  Joseph D Comber; Aykan Karabudak; Xiaofang Huang; Paolo A Piazza; Ernesto T A Marques; Ramila Philip
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 2.  Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections.

Authors:  Anuja Mathew; Elizabeth Townsley; Francis A Ennis
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

Review 3.  Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine.

Authors:  Hui Xuan Lim; Jianhua Lim; Chit Laa Poh
Journal:  Med Microbiol Immunol       Date:  2021-01-30       Impact factor: 3.402

Review 4.  MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines.

Authors:  Joseph D Comber; Ramila Philip
Journal:  Ther Adv Vaccines       Date:  2014-05

5.  A novel immunization approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles.

Authors:  Xiaofang Huang; Aykan Karabudak; Joseph D Comber; Mohan Philip; Tulin Morcol; Ramila Philip
Journal:  Hum Vaccin Immunother       Date:  2017-09-21       Impact factor: 3.452

6.  Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications.

Authors:  James S Testa; Ramila Philip
Journal:  Future Virol       Date:  2012-11-01       Impact factor: 1.831

7.  MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response.

Authors:  James S Testa; Vivekananda Shetty; Julie Hafner; Zacharie Nickens; Shivali Kamal; Gomathinayagam Sinnathamby; Ramila Philip
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

Review 8.  Development of Peptide Vaccines in Dengue.

Authors:  Kavita Reginald; Yanqi Chan; Magdalena Plebanski; Chit Laa Poh
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

Review 9.  Human T Cell Response to Dengue Virus Infection.

Authors:  Yuan Tian; Alba Grifoni; Alessandro Sette; Daniela Weiskopf
Journal:  Front Immunol       Date:  2019-09-04       Impact factor: 7.561

10.  MHC Class I Presented T Cell Epitopes as Potential Antigens for Therapeutic Vaccine against HBV Chronic Infection.

Authors:  Joseph D Comber; Aykan Karabudak; Vivekananda Shetty; James S Testa; Xiaofang Huang; Ramila Philip
Journal:  Hepat Res Treat       Date:  2014-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.